Please be advised that Cytox Limited was placed into Liquidation on 4 January 2024, with Simon Farr and Anthony Collier of FRP Advisory Trading Limited being appointed Joint Liquidators of the Company. If you are owed money by Cytox Limited, or require further information about the Liquidation, please do not hesitate to contact firstname.lastname@example.org.
Feb 28, 2019
Cytox White Paper on assessing Alzheimer’s disease risk using polygenic risk scoring biomarkers updated following validation by new study
Cytox’s insightful review of its groundbreaking approach and platform for assessing Alzheimer’s disease risk using polygenic risk scoring (PRS) biomarkers has now been updated following the recent publication of the results of an international collaborative study in the January issue of the Journal of Prevention of Alzheimer’s Disease .
Using PRS analysis based upon Alzheimer’s disease-associated SNPs according to the IGAP study, the authors reported a high predictive accuracy of PRS in pathologically confirmed ApoE3 homozygotes (83%), and equivalent to the predictive accuracy of the whole dataset, indicating that ApoE is an independent risk factor for the disease. From a practical perspective they concluded that the PRS approach will have predictive utility even in ApoE4 negative individuals with implications in clinical trial design.
Dr Richard Pither, CEO of Cytox, commented, “This study by world-renowned Alzheimer’s disease researchers further validates the performance of our current PRS approaches for assessing genetic risk for developing Alzheimer’s disease, including how we identify Alzheimer’s disease risk in ApoE3 homozygote individuals.
I strongly recommend that all those interested in Alzheimer’s disease download our White Paper, which provides the background on our groundbreaking approach to developing new, more targeted, precision-based methods to help drug developers running clinical trials and sponsors of large cohort studies better stratify their subjects based on accelerated disease development risk.”
1. Escott-Price V, Myers A, Huentelman M, Shoai M and Hardy. Polygenic risk score analysis of Alzheimer’s disease in cases without ApoE4 or ApoE2 alleles. J Prev Alz Dis 2019;6(1):16-19